Application US20200330424

CANNABINOID LOZENGE FORMULATION
[+] Show Details

US20200330424

1-115. (canceled) (0)

116. A lozenge composition for controlled release of cannabinoids comprising: (19) (2)

i) a master granule component comprising one or more solid particles and one or more cannabinoids reversibly associated with the one or more solid particles; and

ii) an extragranular component blended with the master granule component comprising one or more extragranular sugar alcohols.

117. The lozenge composition according to claim 116, wherein the weight ratio of the master granule component relative to the one or more extragranular sugar alcohols is from 1:30 to 1:2. (0)

118. The lozenge composition according to claim 116, wherein the one or more solid particles is agglomerated to form a granule together with the one or more cannabinoids. (0)

119. The lozenge composition according to claim 116, wherein the master granule component is a premixture of the one or more solid particles and the one or more cannabinoids. (0)

120. The lozenge composition according to claim 116, wherein the master granule component comprises one or more cannabinoid lipid carriers into which the one or more cannabinoids are located. (2) (0)

123. The lozenge composition according to claim 116, wherein the master granule component is a premixture of the one or more solid particles and the one or more cannabinoids reversibly adsorbed onto the one or more solid particles, the one or more cannabinoids applied by means of spraying. (0)

124. The lozenge composition according to claim 116, wherein the master granule component is a premixture of the one or more solid particles and the one or more cannabinoids reversibly adsorbed onto the one or more solid particles, the one or more cannabinoids applied by means of a thin layer to the surface of the one or more solid particles. (0)

125. The lozenge composition according to claim 116, wherein the weight ratio of the one or more cannabinoids relative to the one or more solid particles is from 1:30 to 1:1. (0)

126. The lozenge composition according to claim 116, wherein the master granule has a volume weighted mean diameter of 10-400 μm. (0)

127. The lozenge composition according to claim 116, wherein the one or more solid particles is water insoluble. (0)

128. The lozenge composition according to claim 116, wherein the one or more solid particles comprises microcrystalline cellulose. (0)

129. The lozenge composition according to claim 116, wherein the one or more solid particles is water-soluble. (0)

130. The lozenge composition according to claim 116, wherein the one or more solid particles comprises one or more sugar alcohols. (0)

131. The lozenge composition according to claim 116, where a content of sugar alcohol in the master granule component is from 5 to 40% by weight of the composition and a content of sugar alcohol in the extracellular component is from 60 to 95% by weight of the of the composition. (0)

132. The lozenge composition according to claim 116, where a content of microcrystalline cellulose in the master granule component is from 2 to 40% by weight of the composition and a content of sugar alcohol in the extracellular component is from 60 to 98% by weight of the of the composition. (0)

133. The lozenge composition according to claim 116, wherein the composition disintegrates in contact with saliva after about 5 minutes. (0)

134. The lozenge composition according to claim 116, wherein the one or more cannabinoids comprises cannabidiol (CBD), cannabidiolic acid (CBDA), cannabidivarin (CBDV), salts and derivatives thereof. (0)

135. The lozenge composition according to claim 116, wherein the one or more cannabinoids comprises tetrahydrocannabinol (THC), tetrahydrocannabinolic acid (THCA), tetrahydrocannabivarin (THCV), salts and derivatives thereof. (0)

136. A package comprising a lozenge composition according to claim 116, the package comprising a material acting as a barrier for the one or more cannabinoids and oxygen. (0)

137. A method of alleviating or treating a medical condition selected from the group consisting of pain, epilepsy, cancer, nausea, inflammation, congenital disorders, neurological disorders, oral infections, dental pain, sleep apnea, psychiatric disorders, gastrointestinal disorders, inflammatory bowel disease, appetite loss, diabetes and fibromyalgia comprising administering a lozenge composition according to claim 116. (0)

138. A lozenge composition for controlled release of cannabinoids comprising: (0) (2)

139. A lozenge composition for controlled release of cannabinoids comprising: (0) (2)

View Abstract and Specification Size

PDF with Images and Document Face >

Full Text Publication >

Application US20200330424

CANNABINOID LOZENGE FORMULATION

Patent Matrix® Search